Akums Drugs & Pharmaceuticals has posted a robust third quarter performance for FY26, delivering strong double-digit growth across key financial and operational metrics, while expanding its regulatory footprint in Europe and the UK.

 

India’s largest Contract Development and Manufacturing Organization (CDMO) reported revenue of Rs 1,160 crore in Q3 FY26, marking a 14.8% year-on-year increase over Rs 1,010 crore in the same period last year. Growth was powered by more than 16% revenue expansion in the CDMO segment, driven by a double-digit surge in volumes.

 

The company’s international branded formulations business more than doubled sequentially, buoyed by demand recovery across its core markets.

 

Operational leverage kicked in during the quarter, with adjusted EBITDA rising 21% year-on-year to Rs 147 crore, compared with Rs 121 crore a year earlier. Margins improved to 12.7%, supported by better capacity utilization and steady ramp-up at newer facilities. Tighter overhead control and portfolio rationalization helped cushion losses in the API and trade generics segment.

 

Adjusted profit after tax (PAT) climbed 29.5% year-on-year to Rs 86 crore, lifting PAT margins to 7.2% from 6.5% last year.

 

For the nine-month period ended FY26, revenue stood at Rs 3,201 crore, up 4.5% year-on-year, while adjusted EBITDA came in at Rs 370 crore.

 

Beyond financial performance, the quarter marked a regulatory milestone. The company received European Union Good Manufacturing Practice (EU GMP) certification for two manufacturing facilities — renewal for its Oral Solids plant and fresh certification for its Oral Liquids plant.

 

Akums also secured its first approval from the UK MHRA for Rivaroxaban tablets, strengthening its foothold in regulated markets.

 

Commenting on the development, Sandeep Jain, Managing Director, stated, “The EU GMP certifications reflect the strength of our compliant infrastructure, robust quality systems, and the expertise of our skilled teams. We remain focused on disciplined growth while steadily strengthening our presence in regulated markets.”

 

Sanjeev Jain, Managing Director, added, “Our continued focus on operational excellence and disciplined growth is aligned with our long-term global vision, enabling us to expand responsibly across regulated markets and strengthen partnerships worldwide.”

 

With accelerating CDMO momentum, expanding international demand, and fresh regulatory clearances in Europe and the UK, Akums appears firmly on track in its ambition to become a global manufacturing powerhouse.